The aztreonam avibactam mechanism of action is based on the complementary activity of two components: aztreonam, a monobactam antibiotic, and avibactam, a non-beta-lactam beta-lactamase inhibitor.
Aztreonam targets bacterial cell-wall synthesis by binding primarily to penicillin-binding protein 3 (PBP3), while avibactam protects aztreonam from hydrolysis by several serine beta-lactamases. Importantly, avibactam does not directly inhibit metallo-beta-lactamases (MBLs). Instead, aztreonam’s intrinsic stability against MBL hydrolysis and avibactam’s inhibition of accompanying serine beta-lactamases create the rationale for the combination.
This mechanism is particularly relevant when discussing resistant Gram-negative bacteria, including Enterobacterales that produce MBLs such as NDM, VIM or IMP.
What Is the Aztreonam Avibactam Mechanism of Action?
Aztreonam-avibactam works through complementary mechanisms:
- Aztreonam binds PBP3 and interferes with bacterial cell-wall synthesis.
- Aztreonam is relatively stable against hydrolysis by Class B MBLs.
- Avibactam inhibits several serine beta-lactamases that can hydrolyze aztreonam.
- This protects aztreonam from enzymatic degradation and allows its antibacterial activity to be maintained against susceptible organisms.
The combination therefore addresses two different components of beta-lactam resistance.
A simplified representation is:
Aztreonam → PBP3 inhibition → impaired cell-wall synthesis
while:
Avibactam → serine β-lactamase inhibition → protection of aztreonam
The 2026 literature continues to describe this complementary mechanism as the central rationale for aztreonam-avibactam against resistant Enterobacterales.
How Does Aztreonam Work?
Aztreonam belongs to the monobactam class of beta-lactam antibiotics.
Its antibacterial effect comes from interference with bacterial cell-wall synthesis.
Aztreonam targets PBP3
Aztreonam binds primarily to penicillin-binding protein 3 (PBP3) in susceptible Gram-negative bacteria.
PBPs participate in the final stages of peptidoglycan synthesis and cell-wall construction. Inhibition of PBP3 disrupts normal cell-wall formation, ultimately contributing to bacterial cell death.
FDA microbiology documentation identifies PBP3 as the principal target of aztreonam.
This is an important distinction because aztreonam does not work by directly inhibiting beta-lactamases.
Its target is the bacterial cell-wall synthesis machinery.
Why Is Aztreonam Important Against MBLs?
Metallo-beta-lactamases represent a major resistance mechanism among Gram-negative bacteria.
Examples include:
- NDM
- VIM
- IMP
These enzymes belong to Ambler Class B beta-lactamases and can hydrolyze many beta-lactam antibiotics.
Aztreonam has an important structural advantage: it is stable against hydrolysis by most Class B MBLs, including NDM, VIM and IMP.
However, this does not mean that aztreonam alone is automatically effective against every MBL-producing isolate.
Why?
Because MBL-producing organisms can also carry other beta-lactamases.
For example, an organism may produce an MBL together with:
- ESBLs
- AmpC enzymes
- KPC
- OXA-type enzymes
These additional enzymes can compromise aztreonam.
This is where avibactam becomes important.
What Does Avibactam Do?
Avibactam is a non-beta-lactam beta-lactamase inhibitor.
Unlike aztreonam, its primary role is not to kill bacteria directly.
Instead, avibactam inhibits susceptible beta-lactamases that can hydrolyze beta-lactam antibiotics.
FDA microbiology data describe avibactam as a diazabicyclooctane inhibitor that forms a reversible covalent interaction with the active site of serine beta-lactamases.
Avibactam has activity against several important serine beta-lactamase classes, including:
- Class A
- Class C
- some Class D enzymes
This includes important enzymes such as ESBLs, AmpC and certain serine carbapenemases.
Does Avibactam Inhibit MBLs?
No.
This is one of the most important points in understanding the aztreonam avibactam mechanism of action.
Avibactam does not directly inhibit Class B metallo-beta-lactamases such as:
- NDM
- VIM
- IMP
Instead, the combination relies on two complementary properties:
Aztreonam: remains stable against MBL-mediated hydrolysis.
Avibactam: inhibits relevant serine beta-lactamases that may also be produced by the same organism.
This distinction should always be maintained when explaining aztreonam-avibactam.
The 2026 FDA review explicitly states that avibactam does not inhibit Class B MBLs.
How Aztreonam and Avibactam Work Together
The mechanism can be understood as a sequence.
Step 1: The bacterium produces beta-lactamases
A resistant Gram-negative bacterium may produce multiple beta-lactamases.
Some may be MBLs, while others may be serine beta-lactamases.
Step 2: Aztreonam encounters the resistance enzymes
Aztreonam is stable against hydrolysis by most Class B MBLs.
However, other beta-lactamases can still hydrolyze aztreonam.
Step 3: Avibactam inhibits susceptible serine beta-lactamases
Avibactam inhibits relevant Class A, Class C and some Class D beta-lactamases.
This reduces enzymatic degradation of aztreonam.
Step 4: Aztreonam reaches its bacterial target
With susceptible beta-lactamases inhibited, aztreonam can maintain activity against its target, PBP3.
Step 5: Cell-wall synthesis is disrupted
PBP3 inhibition interferes with peptidoglycan synthesis and bacterial cell-wall formation.
This produces the antibacterial effect.
Aztreonam Avibactam Mechanism Against NDM-Producing Bacteria
NDM is a Class B metallo-beta-lactamase.
Because avibactam does not inhibit NDM, it would be inaccurate to describe avibactam as an NDM inhibitor.
Instead, the mechanism is complementary.
NDM → aztreonam remains relatively stable
while:
ESBL/AmpC/other susceptible serine β-lactamases → inhibited by avibactam
This provides the mechanistic rationale for activity against certain NDM-producing Enterobacterales.
A large 2026 global collection study evaluated 490 MBL-producing Enterobacterales isolates and reported that all were susceptible to aztreonam-avibactam under the study’s applied EUCAST or FDA breakpoint criteria. These were microbiological susceptibility findings, not evidence that every MBL-producing infection will respond clinically.
Aztreonam Avibactam and PBP3
PBP3 is central to the antibacterial component of the combination.
Aztreonam binds PBP3 and disrupts the normal process of bacterial cell-wall synthesis.
This target also helps explain why alterations in PBP3 can contribute to resistance.
Recent literature identifies PBP3 modifications, beta-lactamase variants, porin changes and efflux alterations among mechanisms that can affect aztreonam-avibactam susceptibility.
Therefore, the mechanism of action and resistance mechanism should be considered together.
Why Beta-Lactamase Combinations Matter
Beta-lactam antibiotics can be highly effective against susceptible bacteria, but beta-lactamases can destroy or modify these antibiotics before they reach their bacterial targets.
A beta-lactamase inhibitor can therefore protect the partner antibiotic.
The concept is:
Without effective inhibition
Beta-lactam → beta-lactamase hydrolysis → reduced antibacterial activity
With appropriate inhibitor activity
Beta-lactam → protected from susceptible beta-lactamase → target engagement → antibacterial effect
Aztreonam-avibactam applies this principle in a distinctive way because aztreonam already has stability against MBLs, while avibactam addresses several serine beta-lactamases.
Aztreonam Avibactam vs Aztreonam Alone
The presence of avibactam changes the resistance environment in which aztreonam operates.
| Feature | Aztreonam | Aztreonam + Avibactam |
|---|---|---|
| Main antibacterial target | PBP3 | PBP3 through aztreonam |
| MBL stability | Yes, against many Class B MBLs | Retained |
| Serine β-lactamase protection | Limited | Avibactam inhibits susceptible enzymes |
| Avibactam activity | Not applicable | Class A, C and some D β-lactamases |
| Direct MBL inhibition by avibactam | — | No |
| Main mechanistic concept | PBP3 inhibition | PBP3 inhibition + β-lactamase protection |
This is why the combination should not simply be described as “a stronger form of aztreonam.”
It has a distinct resistance-management mechanism.
Does Aztreonam Avibactam Work Against Every Resistant Bacterium?
No.
Mechanistic rationale does not mean universal activity.
Aztreonam-avibactam has demonstrated activity against susceptible Enterobacterales, including many MBL-producing isolates, but susceptibility can vary between organisms and resistance mechanisms.
The 2026 review literature identifies several potential resistance pathways, including:
- PBP3 alterations
- beta-lactamase variants
- porin changes
- efflux-related mechanisms
and emphasizes that resistance mechanisms can differ between bacterial species.
Therefore, susceptibility testing remains important.
Mechanism explains potential activity; AST determines the susceptibility phenotype of the tested isolate.
Aztreonam Avibactam Mechanism and Resistance
Resistance to aztreonam-avibactam can arise despite the complementary mechanism.
Recent 2026 research in Enterobacter identified combinations of AmpC-related mutations and increased ampC expression associated with aztreonam-avibactam resistance.
This illustrates an important principle:
A beta-lactamase inhibitor can suppress susceptible enzymes, but bacterial evolution can alter the enzyme, target or permeability environment.
Consequently, ongoing surveillance and susceptibility testing remain important as aztreonam-avibactam use increases.
What Makes the Combination Mechanistically Different?
The key feature is division of roles.
Aztreonam provides the antibacterial target activity
It binds PBP3 and interferes with bacterial cell-wall synthesis.
Avibactam provides beta-lactamase protection
It inhibits susceptible serine beta-lactamases.
MBL stability provides another layer
Aztreonam’s stability against many Class B MBLs allows it to retain activity where many other beta-lactams are hydrolyzed.
Together, these properties create a mechanistic strategy particularly relevant to Gram-negative bacteria carrying combinations of beta-lactamases.
Aztreonam Avibactam Mechanism and Meblanios
Meblanios is an Aztreonam and Avibactam injection from AIONIOS Pharma.
The scientific mechanism described in this article applies to the aztreonam-avibactam combination. Product-specific prescribing, regulatory status and clinical-use claims should always be based on the applicable product information.
For readers looking for product information, see the Meblanios product page.
For the broader scientific background, see:
- Aztreonam and Avibactam
- MBL Resistance and Aztreonam Avibactam
- Aztreonam Avibactam Susceptibility Testing
- Aztreonam Avibactam Pharmacokinetics
- Aztreonam Avibactam Clinical Trials
This is exactly where we’re going to build the Meblanios → Aztreonam + Avibactam association without turning every article into a Meblanios article.
Frequently Asked Questions
What is the mechanism of action of aztreonam-avibactam?
Aztreonam binds primarily to PBP3 and disrupts bacterial cell-wall synthesis, while avibactam inhibits several serine beta-lactamases that can hydrolyze aztreonam.
Does avibactam inhibit NDM?
No. NDM is a Class B metallo-beta-lactamase, and avibactam does not directly inhibit Class B MBLs. Its role is to inhibit susceptible serine beta-lactamases that may be produced alongside an MBL.
Why is aztreonam useful against MBL-producing bacteria?
Aztreonam is stable against hydrolysis by most Class B MBLs, including NDM, VIM and IMP. However, co-produced serine beta-lactamases can still compromise aztreonam, which is why the combination with avibactam is mechanistically important.
What does aztreonam target?
Aztreonam primarily targets PBP3, a penicillin-binding protein involved in bacterial cell-wall synthesis.
Is aztreonam-avibactam effective against every MBL-producing organism?
No. Activity depends on the organism, resistance mechanisms and susceptibility of the individual isolate. In-vitro activity should not be equated with guaranteed clinical efficacy.
Can bacteria become resistant to aztreonam-avibactam?
Yes. Reported mechanisms include PBP3 alterations, beta-lactamase changes, porin modifications and efflux-related mechanisms. Recent 2026 work has also described AmpC-related mechanisms in resistant Enterobacter.
Conclusion
The aztreonam avibactam mechanism of action is based on complementary activity rather than direct inhibition of every beta-lactamase.
Aztreonam provides the antibacterial activity by targeting PBP3 and is naturally stable against many Class B MBLs. Avibactam protects aztreonam by inhibiting several serine beta-lactamases, including important Class A and Class C enzymes and some Class D enzymes.
The combination is therefore particularly relevant to complex beta-lactam resistance in Gram-negative bacteria, especially MBL-producing Enterobacterales. However, resistance mechanisms can still reduce activity, making susceptibility testing and appropriate clinical interpretation essential.
For AIONIOS Pharma’s product context, Meblanios represents the Aztreonam + Avibactam combination, while the supporting scientific content above helps establish the broader topical relationship between the combination, beta-lactamase resistance and MBL-producing bacteria.